Sclerosing encapsulating peritonitis (SEP) in patients on continuous ambulatory peritoneal dialysis. Definition, diagnosis and treatment recommendations, 1996 update.

Nomoto, Yasuo; Kawaguchi, Yoshindo; Sakai, Shinji; Honda, Hiroshi; Kubo, Hitoshi; Ohira, Suguru; Honma, Sato; Yamagata, Kunihiro; Miura, Yuri; Kimura, Yasuo; Kuriyama, Satoru; Hamada, Chikuma; Sanaka, Tsutomu; Nakao, Toshiyuki; Honda, Masashi; Kumano, Kazuo; Yokota, Shinji; Suga, Takao; Môri, N.; Shimomura, Akira; Kim, Masao; Imada, Akio; Tanaka, Ryoji; Kawanishi, Hideki; Edakuni, Setsuo; Fukui, Hiroyoshi; Kurokawa, Kiyoshi

doi:10.4009/jsdt.30.1013

Cited by 20 publications

(44 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Staphylococcus sp. were commonly found in both groups, but not significantly more in EPS patients, contrary to other reports . Usually, inappropriate usage of antibiotics leads to drug‐resistant species, such as methicillin‐resistant Staphylococcus aureus (MRSA), methicillin‐resistant Staphylococcus epidermis (MRSE) and vancomycin‐resistance enterococci .…”

Section: Discussionmentioning

confidence: 72%

Risk Factors for Encapsulating Peritoneal Sclerosis in Long‐Term Peritoneal Dialysis: A Retrospective Observational Study

et al. 2013

View full text Add to dashboard Cite

Encapsulating peritoneal sclerosis (EPS) is a serious complication that occurs in patients with long-term peritoneal dialysis (PD). Investigation of risk factors that contribute to EPS in patients on long-term PD therapy is needed. In a retrospective, observational study, data were collected for 107 patients treated with PD therapy for more than 5 years. Fifty cases of EPS were compared with 57 cases of non-EPS. To evaluate the impact of PD-associated peritonitis in EPS, univariate and multivariate logistic regression models were applied. Episodes of peritonitis, number of peritonitis episodes and the duration of peritonitis were included as explanatory variables in addition to previously reported risk factors. D/P Cr and serum β2MG levels in the EPS and non-EPS groups were: 0.82 ± 0.10 and 0.67 ± 0.12 (P < 0.01), and 33.8 ± 8.54 and 29.2 ± 8.18 mg/L (P < 0.01), respectively. Episodes of peritonitis, number of peritonitis episodes and the duration of peritonitis was 68% and 42% (P < 0.01), 1.80 ± 2.19 and 0.75 ± 1.07 times (P < 0.01), and 18.1 ± 15.3 and 10.2 ± 4.90 days (P < 0.01), in the EPS and non-EPS groups, respectively. Furthermore, multivariate logistic regression models demonstrated that both D/P Cr and the duration of peritonitis were independently associated with EPS (P < 0.01 and P < 0.05, respectively). In patients on long-term PD therapy, D/P Cr and the duration of peritonitis are independently associated with EPS. Earlier treatment to promote an early recovery from PD-associated peritonitis could be critical in preventing EPS.

show abstract

Section: Discussionmentioning

confidence: 72%

Risk Factors for Encapsulating Peritoneal Sclerosis in Long‐Term Peritoneal Dialysis: A Retrospective Observational Study

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In our study, the mean UF volume of the SEP cases with impaired UF was less than 300 ml/m 2 per day, which corresponds to less than 500 ml/1.73 m 2 per day in adults. Based on our results, the Japanese SEP Study Group added a criterion for pediatric patients in their recent report [11], which is an UF volume of less than 300 ml/m 2 per day with dialysate bags of 2.5% glucose solution four times per day in patients with no residual urine volume. The performance of the PET is useful for characterizing the patient's peritoneal membrane transport capacity.…”

Section: Discussionmentioning

confidence: 98%

Sclerosing encapsulating peritonitis in pediatric peritoneal dialysis patients

Hoshii¹,

Honda

Itami

et al. 2000

Pediatric Nephrology

View full text Add to dashboard Cite

The aim of this study was to define the incidence and characteristics of sclerosing encapsulating peritonitis (SEP) in pediatric peritoneal dialysis (PD) patients in Japan. A questionnaire was sent to all dialysis units with at least two pediatric PD patients. Among 687 patients registered, 11 cases (1.6%) of SEP were diagnosed. The mean age of patients with SEP at the start of PD was 9.7+/-3.6 years and at SEP diagnosis, 19.1+/-3.8 years. All patients had undergone PD for more than 5 years, and the mean PD duration was 9.6+/-3.3 years. SEP was diagnosed in 6.6% and 12% of patients dialyzed for >5 years and >8 years, respectively. The incidence of peritonitis among patients with SEP was not different from that among the Japanese pediatric registry. All patients had virtually no residual urine volume and 9 had impaired peritoneal ultrafiltration. Peritoneal calcification was the most-frequent radiological finding. Peritoneal biopsy was performed in 7 patients and confirmed sclerotic peritonitis in all. Ten patients transferred to hemodialysis, and only 1 patient underwent surgery. Three patients died. We recommend that patients on PD for more than 5 years who have impaired peritoneal ultrafiltration or peritoneal calcification should be carefully managed as presumptive cases of SEP.

show abstract

“…The pharmacological mode of action of corticosteroids in SEP is unclear. Several working groups concluded that corticosteroids were potentially effective in the treatment of SEP because the exuberant fibroneogenesis in such cases should be controlled by drugs preventing formation of peritoneal effusion and fibrin deposition (Junor and McMillan 1993, Nomoto and others 1998).…”

Section: Discussionmentioning

confidence: 99%

Use of tamoxifen in a German shepherd dog with sclerosing encapsulating peritonitis

Etchepareborde

Heimann

Cohen‐Solal

et al. 2010

J of Small Animal Practice

View full text Add to dashboard Cite

A German shepherd dog was diagnosed with sclerosing encapsulating peritonitis after an episode of peritonitis caused by a free intra-abdominal foreign body (stick). The foreign body had initially been treated by surgical removal and abdominal lavage. Postoperatively, peritoneal effusion persisted despite the use of methylprednisolone for 1 month and a second surgical exploration and abdominal lavage. After a third surgery at our institution (to breakdown abdominal adhesions) followed by open abdominal drainage, treatment with tamoxifen orally was initiated and within 2 weeks the dog's condition improved dramatically. Two months later, no fluid was present in the abdomen. The only apparent adverse reaction to tamoxifen therapy was swelling of the vulva. In humans, sclerosing encapsulating peritonitis is a known life-threatening complication following peritoneal dialysis. In veterinary medicine, most animals with sclerosing encapsulating peritonitis die because of chronic weight loss, peritoneal effusion and progression of concurrent disease. This dog's condition was unresponsive to methylprednisolone alone but was successfully treated with aggressive surgery including enterolysis and open abdominal lavage and the addition of tamoxifen.

show abstract

Sclerosing encapsulating peritonitis (SEP) in patients on continuous ambulatory peritoneal dialysis. Definition, diagnosis and treatment recommendations, 1996 update.

Cited by 20 publications

References 0 publications

Risk Factors for Encapsulating Peritoneal Sclerosis in Long‐Term Peritoneal Dialysis: A Retrospective Observational Study

Risk Factors for Encapsulating Peritoneal Sclerosis in Long‐Term Peritoneal Dialysis: A Retrospective Observational Study

Sclerosing encapsulating peritonitis in pediatric peritoneal dialysis patients

Use of tamoxifen in a German shepherd dog with sclerosing encapsulating peritonitis

Contact Info

Product

Resources

About